Global Quadrivalent Meningococcal Vaccine Market Growth 2023-2029

Global Quadrivalent Meningococcal Vaccine Market Growth 2023-2029


The global Quadrivalent Meningococcal Vaccine market size is projected to grow from US$ 181 million in 2022 to US$ 273.9 million in 2029; it is expected to grow at a CAGR of 6.1% from 2023 to 2029.

Many countries have implemented meningococcal vaccination programs, especially targeting high-risk groups such as infants, adolescents and university students. Inclusion or recommendation of quadrivalent meningococcal vaccines in national immunization schedules can significantly influence the market demand.

The meningococcal quadrivalent vaccine protects against 4 types of meningococcus: types A, C, Y, and W.

LPI (LP Information)' newest research report, the “Quadrivalent Meningococcal Vaccine Industry Forecast” looks at past sales and reviews total world Quadrivalent Meningococcal Vaccine sales in 2022, providing a comprehensive analysis by region and market sector of projected Quadrivalent Meningococcal Vaccine sales for 2023 through 2029. With Quadrivalent Meningococcal Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Quadrivalent Meningococcal Vaccine industry.

This Insight Report provides a comprehensive analysis of the global Quadrivalent Meningococcal Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Quadrivalent Meningococcal Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Quadrivalent Meningococcal Vaccine market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Quadrivalent Meningococcal Vaccine and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Quadrivalent Meningococcal Vaccine.

This report presents a comprehensive overview, market shares, and growth opportunities of Quadrivalent Meningococcal Vaccine market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type
Polysaccharide Vaccine
Conjugate Vaccine

Segmentation by application
Hospital
Clinic

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Sanofi-Pasteur
Walvax
Chengdu Kanghua Biological Products Co., Ltd.
Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd.
Zhejiang Tianyuan Biopharmaceutical Co., Ltd.
Beijing Institute of Biological Products Co., Ltd.
CanSino Biological Co., Ltd.
Hualan Biological Vaccine Co., Ltd.
Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Quadrivalent Meningococcal Vaccine market?

What factors are driving Quadrivalent Meningococcal Vaccine market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Quadrivalent Meningococcal Vaccine market opportunities vary by end market size?

How does Quadrivalent Meningococcal Vaccine break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.


*This is a tentative TOC and the final deliverable is subject to change.*
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Quadrivalent Meningococcal Vaccine Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Quadrivalent Meningococcal Vaccine by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Quadrivalent Meningococcal Vaccine by Country/Region, 2018, 2022 & 2029
2.2 Quadrivalent Meningococcal Vaccine Segment by Type
2.2.1 Polysaccharide Vaccine
2.2.2 Conjugate Vaccine
2.3 Quadrivalent Meningococcal Vaccine Sales by Type
2.3.1 Global Quadrivalent Meningococcal Vaccine Sales Market Share by Type (2018-2023)
2.3.2 Global Quadrivalent Meningococcal Vaccine Revenue and Market Share by Type (2018-2023)
2.3.3 Global Quadrivalent Meningococcal Vaccine Sale Price by Type (2018-2023)
2.4 Quadrivalent Meningococcal Vaccine Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.5 Quadrivalent Meningococcal Vaccine Sales by Application
2.5.1 Global Quadrivalent Meningococcal Vaccine Sale Market Share by Application (2018-2023)
2.5.2 Global Quadrivalent Meningococcal Vaccine Revenue and Market Share by Application (2018-2023)
2.5.3 Global Quadrivalent Meningococcal Vaccine Sale Price by Application (2018-2023)
3 Global Quadrivalent Meningococcal Vaccine by Company
3.1 Global Quadrivalent Meningococcal Vaccine Breakdown Data by Company
3.1.1 Global Quadrivalent Meningococcal Vaccine Annual Sales by Company (2018-2023)
3.1.2 Global Quadrivalent Meningococcal Vaccine Sales Market Share by Company (2018-2023)
3.2 Global Quadrivalent Meningococcal Vaccine Annual Revenue by Company (2018-2023)
3.2.1 Global Quadrivalent Meningococcal Vaccine Revenue by Company (2018-2023)
3.2.2 Global Quadrivalent Meningococcal Vaccine Revenue Market Share by Company (2018-2023)
3.3 Global Quadrivalent Meningococcal Vaccine Sale Price by Company
3.4 Key Manufacturers Quadrivalent Meningococcal Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Quadrivalent Meningococcal Vaccine Product Location Distribution
3.4.2 Players Quadrivalent Meningococcal Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Quadrivalent Meningococcal Vaccine by Geographic Region
4.1 World Historic Quadrivalent Meningococcal Vaccine Market Size by Geographic Region (2018-2023)
4.1.1 Global Quadrivalent Meningococcal Vaccine Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Quadrivalent Meningococcal Vaccine Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Quadrivalent Meningococcal Vaccine Market Size by Country/Region (2018-2023)
4.2.1 Global Quadrivalent Meningococcal Vaccine Annual Sales by Country/Region (2018-2023)
4.2.2 Global Quadrivalent Meningococcal Vaccine Annual Revenue by Country/Region (2018-2023)
4.3 Americas Quadrivalent Meningococcal Vaccine Sales Growth
4.4 APAC Quadrivalent Meningococcal Vaccine Sales Growth
4.5 Europe Quadrivalent Meningococcal Vaccine Sales Growth
4.6 Middle East & Africa Quadrivalent Meningococcal Vaccine Sales Growth
5 Americas
5.1 Americas Quadrivalent Meningococcal Vaccine Sales by Country
5.1.1 Americas Quadrivalent Meningococcal Vaccine Sales by Country (2018-2023)
5.1.2 Americas Quadrivalent Meningococcal Vaccine Revenue by Country (2018-2023)
5.2 Americas Quadrivalent Meningococcal Vaccine Sales by Type
5.3 Americas Quadrivalent Meningococcal Vaccine Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Quadrivalent Meningococcal Vaccine Sales by Region
6.1.1 APAC Quadrivalent Meningococcal Vaccine Sales by Region (2018-2023)
6.1.2 APAC Quadrivalent Meningococcal Vaccine Revenue by Region (2018-2023)
6.2 APAC Quadrivalent Meningococcal Vaccine Sales by Type
6.3 APAC Quadrivalent Meningococcal Vaccine Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Quadrivalent Meningococcal Vaccine by Country
7.1.1 Europe Quadrivalent Meningococcal Vaccine Sales by Country (2018-2023)
7.1.2 Europe Quadrivalent Meningococcal Vaccine Revenue by Country (2018-2023)
7.2 Europe Quadrivalent Meningococcal Vaccine Sales by Type
7.3 Europe Quadrivalent Meningococcal Vaccine Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Quadrivalent Meningococcal Vaccine by Country
8.1.1 Middle East & Africa Quadrivalent Meningococcal Vaccine Sales by Country (2018-2023)
8.1.2 Middle East & Africa Quadrivalent Meningococcal Vaccine Revenue by Country (2018-2023)
8.2 Middle East & Africa Quadrivalent Meningococcal Vaccine Sales by Type
8.3 Middle East & Africa Quadrivalent Meningococcal Vaccine Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Quadrivalent Meningococcal Vaccine
10.3 Manufacturing Process Analysis of Quadrivalent Meningococcal Vaccine
10.4 Industry Chain Structure of Quadrivalent Meningococcal Vaccine
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Quadrivalent Meningococcal Vaccine Distributors
11.3 Quadrivalent Meningococcal Vaccine Customer
12 World Forecast Review for Quadrivalent Meningococcal Vaccine by Geographic Region
12.1 Global Quadrivalent Meningococcal Vaccine Market Size Forecast by Region
12.1.1 Global Quadrivalent Meningococcal Vaccine Forecast by Region (2024-2029)
12.1.2 Global Quadrivalent Meningococcal Vaccine Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Quadrivalent Meningococcal Vaccine Forecast by Type
12.7 Global Quadrivalent Meningococcal Vaccine Forecast by Application
13 Key Players Analysis
13.1 Sanofi-Pasteur
13.1.1 Sanofi-Pasteur Company Information
13.1.2 Sanofi-Pasteur Quadrivalent Meningococcal Vaccine Product Portfolios and Specifications
13.1.3 Sanofi-Pasteur Quadrivalent Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Sanofi-Pasteur Main Business Overview
13.1.5 Sanofi-Pasteur Latest Developments
13.2 Walvax
13.2.1 Walvax Company Information
13.2.2 Walvax Quadrivalent Meningococcal Vaccine Product Portfolios and Specifications
13.2.3 Walvax Quadrivalent Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Walvax Main Business Overview
13.2.5 Walvax Latest Developments
13.3 Chengdu Kanghua Biological Products Co., Ltd.
13.3.1 Chengdu Kanghua Biological Products Co., Ltd. Company Information
13.3.2 Chengdu Kanghua Biological Products Co., Ltd. Quadrivalent Meningococcal Vaccine Product Portfolios and Specifications
13.3.3 Chengdu Kanghua Biological Products Co., Ltd. Quadrivalent Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Chengdu Kanghua Biological Products Co., Ltd. Main Business Overview
13.3.5 Chengdu Kanghua Biological Products Co., Ltd. Latest Developments
13.4 Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd.
13.4.1 Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Company Information
13.4.2 Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Quadrivalent Meningococcal Vaccine Product Portfolios and Specifications
13.4.3 Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Quadrivalent Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Main Business Overview
13.4.5 Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Latest Developments
13.5 Zhejiang Tianyuan Biopharmaceutical Co., Ltd.
13.5.1 Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Company Information
13.5.2 Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Quadrivalent Meningococcal Vaccine Product Portfolios and Specifications
13.5.3 Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Quadrivalent Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Main Business Overview
13.5.5 Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Latest Developments
13.6 Beijing Institute of Biological Products Co., Ltd.
13.6.1 Beijing Institute of Biological Products Co., Ltd. Company Information
13.6.2 Beijing Institute of Biological Products Co., Ltd. Quadrivalent Meningococcal Vaccine Product Portfolios and Specifications
13.6.3 Beijing Institute of Biological Products Co., Ltd. Quadrivalent Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Beijing Institute of Biological Products Co., Ltd. Main Business Overview
13.6.5 Beijing Institute of Biological Products Co., Ltd. Latest Developments
13.7 CanSino Biological Co., Ltd.
13.7.1 CanSino Biological Co., Ltd. Company Information
13.7.2 CanSino Biological Co., Ltd. Quadrivalent Meningococcal Vaccine Product Portfolios and Specifications
13.7.3 CanSino Biological Co., Ltd. Quadrivalent Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 CanSino Biological Co., Ltd. Main Business Overview
13.7.5 CanSino Biological Co., Ltd. Latest Developments
13.8 Hualan Biological Vaccine Co., Ltd.
13.8.1 Hualan Biological Vaccine Co., Ltd. Company Information
13.8.2 Hualan Biological Vaccine Co., Ltd. Quadrivalent Meningococcal Vaccine Product Portfolios and Specifications
13.8.3 Hualan Biological Vaccine Co., Ltd. Quadrivalent Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Hualan Biological Vaccine Co., Ltd. Main Business Overview
13.8.5 Hualan Biological Vaccine Co., Ltd. Latest Developments
13.9 Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd.
13.9.1 Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Company Information
13.9.2 Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Quadrivalent Meningococcal Vaccine Product Portfolios and Specifications
13.9.3 Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Quadrivalent Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Main Business Overview
13.9.5 Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Latest Developments
14 Research Findings and Conclusion

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings